[1]. Cassier, P.A., et al., A prospective epidemiological study of new incident GISTs during two consecutive years in Rhone Alpes region: incidence and molecular distribution of GIST in a European region. Br J Cancer, 2010. 103(2): p. 165-70.
[2]. Joensuu, H., P. Hohenberger and C.L. Corless, Gastrointestinal stromal tumour. Lancet, 2013. 382(9896): p. 973-83.
[3]. Joensuu, H., et al., Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol, 2012. 13(3): p. 265-74.
[4]. Emile, J.F., et al., Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol, 2012. 29(3): p. 1765-72.
[5]. Zhang, L., et al., Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol, 2010. 34(1): p. 53-64.
[6]. Medeiros, F., et al., KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol, 2004. 28(7): p. 889-94.
[7]. West, R.B., et al., The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol, 2004. 165(1): p. 107-13.
[8]. Joensuu, H., et al., KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. J Clin Oncol, 2015. 33(6): p. 634-42.
[9]. Hirota, S., et al., Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998. 279(5350): p. 577-80.
[10]. Rubin, B.P., Gastrointestinal stromal tumours: an update. Histopathology, 2006. 48(1): p. 83-96.
[11]. Tran, T., J.A. Davila and H.B. El-Serag, The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol, 2005. 100(1): p. 162-8.
[12]. Verweij, J., et al., Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer, 2003. 39(14): p. 2006-11.
[13]. Corless, C.L., et al., Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol, 2014. 32(15): p. 1563-70.
[14]. Casali, P.G., et al., Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol, 2015. 33(36): p. 4276-83.
[15]. Wang, S.Y., et al., Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome. Cancers (Basel), 2019. 11(3).
[16]. Haller, F., et al., Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol, 2007. 14(2): p. 526-32.
[17]. Choi, H., et al., Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol, 2007. 25(13): p. 1753-9.
[18]. Raut, C.P., et al., Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol, 2006. 24(15): p. 2325-31.
[19]. Miettinen, M. and J. Lasota, Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol, 2006. 23(2): p. 70-83.
[20]. Tang, S., et al., Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST). World J Surg Oncol, 2017. 15(1): p. 79.
[21]. Tielen, R., et al., Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. Eur J Surg Oncol, 2013. 39(2): p. 150-5.
[22]. Casali, P.G., et al., Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2018. 29(Suppl 4): p. iv267.
[23]. von Mehren, M., et al., Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2018. 16(5): p. 536-563.
[24]. Lee, J.C., et al., Preoperative tyrosine kinase inhibitors risks bowel anastomotic healing in patients with advanced primary and recurrent/metastatic gastrointestinal stromal tumors--- A rose has its thorns. Eur J Surg Oncol, 2019. 45(2): p. 153-159.
[25]. Li, J., et al., Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients. World J Gastroenterol, 2012. 18(7): p. 698-703.
[26]. Engin, G., et al., Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report. World J Radiol, 2017. 9(9): p. 365-370.
[27]. Heinrich, M.C., et al., Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol, 2003. 21(23): p. 4342-9.
[28]. Debiec-Rychter, M., et al., KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer, 2006. 42(8): p. 1093-103.
[29]. Xu, C.W., et al., Analysis of mutation of the c-Kit gene and PDGFRA in gastrointestinal stromal tumors. Exp Ther Med, 2015. 10(3): p. 1045-1051.
[30]. Spitaleri, G., et al., Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K). Onco Targets Ther, 2015. 8: p. 1997-2003.
[31]. Hanson, J.A., et al., Small-intestinal rhabdoid gastrointestinal stromal tumor (GIST): mutation analysis and clinical implications of a rare morphological variant. Int J Surg Pathol, 2011. 19(5): p. 653-7.
[32]. Wang, D., et al., Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol, 2012. 19(4): p. 1074-80.
[33]. Blanke, C.D., et al., Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol, 2008. 26(4): p. 620-5.
[34]. Nishida, T., et al., Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol, 2008. 13(3): p. 244-51.
[35]. Kurokawa, Y., et al., Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer, 2017. 117(1): p. 25-32.